NMR metabolomic of frontal cortex extracts First study comparing two neurodegenerative diseases, Alzheimer disease and amyotrophic lateral sclerosis
| Autor: | L. Le Moyec, Fabien Dutheil, Mohamed N. Triba, Carole Marbeuf-Gueye, Marie-Anne Loriot, Philippe Beaune, E.P. Botosoa, M. Zhu, C. Duyckaerts |
|---|---|
| Přispěvatelé: | Chimie, Structures et Propriétés de Biomatériaux et d'Agents Thérapeutiques (CSPBAT), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Sorbonne Paris Nord, Régulation de la transcription et maladies génétiques (RTMG), Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Neurologie et thérapeutique expérimentale, IFR70-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Unité de biologie intégrative des adaptations à l'exercice (UBIAE), Université d'Évry-Val-d'Essonne (UEVE)-Institut National de la Santé et de la Recherche Médicale (INSERM) |
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
amyotrophic lateral sclerosis
in vitro study [SDV]Life Sciences [q-bio] Biomedical Engineering Biophysics Context (language use) Creatine proton nuclear magnetic resonance in vivo study 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Metabolomics autopsy 3 hydroxybutyric acid In vivo choline medicine succinic acid Choline qualitative analysis human Amyotrophic lateral sclerosis brain level 030304 developmental biology 0303 health sciences n acetylaspartic acid quantitative analysis frontal cortex lactic acid article medicine.disease metabolomics human tissue 3. Good health Metabolic pathway acetic acid creatine Biochemistry chemistry inositol glutamine Alzheimer's disease alanine glutamic acid Alzheimer disease 030217 neurology & neurosurgery |
| Zdroj: | IRBM IRBM, 2012, 33 (5-6), pp.281-286. ⟨10.1016/j.irbm.2012.08.002⟩ Innovation and Research in BioMedical engineering Innovation and Research in BioMedical engineering, 2012, 33 (5-6), pp.281-286. ⟨10.1016/j.irbm.2012.08.002⟩ |
| ISSN: | 1959-0318 |
| DOI: | 10.1016/j.irbm.2012.08.002⟩ |
| Popis: | International audience; Objective This study was designed to assess the brain metabolites' variability between two neurodegenerative diseases in frontal cortex samples obtained post-mortem. NMR metabolomics was used for the first time in this context. Materials and methods 1H NMR metabolomic was applied to tissue extracts from patients with Alzheimer disease (ALZ) and patients with amyotrophic lateral sclerosis (ALS) to investigate qualitative and quantitative variations of brain metabolites. Results The Alzheimer disease metabolic signature was characterized by a high concentration of alanine, acetate, glutamate and glutamine, and low concentrations of lactate and creatine, while the ALS metabolic signature appears to be marked by high concentrations of lactate, N-acetyl aspartate, creatine, choline and myo-inositol. Moreover, in vitro 1H NMR could detect metabolites such as 3-hydroxybutyrate, alanine, succinate and aspartate that cannot be detected with in vivo NMR. Discussion The neurodegenerative diseases exhibit diverging metabolic pathways. Some of the metabolites responsible for the discrimination between the two diseases were detected before in vivo. However, this in vitro metabolomic investigation demonstrates the involvement of metabolites not detected with in vivo studies. Conclusion Upon these findings, in vitro metabolomics appears to be an efficient tool to investigate the fundamentals of the metabolic pathway modulations in these neurodegenerative diseases to help the interpretation of clinical data obtained with in vivo NMR spectroscopy. © 2012 Elsevier Masson SAS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect